Philip is a physician scientist and cancer biologist with expertise in clinical pathways, drug development and biomarker discovery.

Philip joined Step Pharma in June 2021. Prior to this, he held diverse leadership roles in early stage biotech and small pharma covering oncology drug development and biomarker discovery, with a focus on the use of complex omics technologies to accelerate both the discovery and development of novel therapeutics. Philip is a board certified haematologist with 16 years frontline healthcare experience; he holds a licence to practice in the UK.

Philip is a Member of the Royal College of Physicians, UK, and a Fellow of the Royal College of Pathologists, UK. He was awarded a PhD in molecular cancer biology from the University of Cambridge, UK, and followed this with post-doctoral research at the BC Cancer Agency, Vancouver, Canada. He is an Honorary Professor of Translational Medical at the Hull York Medical School, UK.


Step Pharma is led by a highly motivated management team and an exceptional syndicate of international investors, all driven to bring about a step change in cancer treatment for patients.